Search Results

You are looking at 1 - 10 of 1,763 items for :

Clear All
Full access

John A. Glaspy

in gastric cancer cell growth, angiogenesis, and vessel maturation . J Natl Cancer Inst 2004 ; 96 : 946 – 956 . 20 Dunst J Kuhnt T Strauss HG . Anemia in cervical cancers: impact on survival, patterns of relapse, and association with

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits and Jonathan D. Schoenfeld

carries a high risk of spreading to regional lymph nodes. Nodal recurrences and distant metastases are common, with limited survival for patients with advanced disease. 5 , 6 Treatment of localized MCC is variable, focusing on wide local excision

Full access

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea and William A. Wood

) designation, university affiliation, or high patient volume. For example, treatment at an NCICCC has been shown to attenuate survival disparities among young adults with hematologic malignancies, 1 and treatment by a university-based oncologist has been

Full access

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman and Arya Amini

recommendations. No randomized trials exist, and the results of small retrospective case series have led to contradictory conclusions. A study by the Rare Cancer Network showed improved survival with CRT alone compared with surgery/radiotherapy (RT) or surgery

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore and Xiaomei Ma

Background Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm (MPN) characterized by persistently elevated platelet counts. The median age at diagnosis is 68 years 1 and median survival is 19.8 years, which is inferior to that

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch and Vivien W. Chen

, luminal B, basal-like (triple-negative: ER–/PR–/HER2–), and HER2+/ER–. 1 , 4 These subtypes vary by race and influence survival rate. 5 When physicians prescribe appropriate adjuvant systemic therapies (ASTs) for patients with breast cancer, molecular

Full access

Saber Amin, Michael Baine, Jane Meza and Chi Lin

to be between 8.3 and 14.3 per 100,000 population. 1 The actual incidence rate may be higher because most of the studies reporting the incidence of BMs predate modern imaging and treatments. 1 Furthermore, improved imaging and prolonged survival of

Full access

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli and Pierre I. Karakiewicz

Background Conditional survival (CS) is routinely used in clinical practice. Specifically, clinicians invariably adjust the prognosis of individual patients according to the duration of event-free follow-up. Patients with longer event-free follow

Full access

Amanda Putri Rahmadian, Seanthel Delos Santos, Shruti Parshad, Louis Everest, Matthew C. Cheung and Kelvin K. Chan

Background In recent years, immunotherapy has emerged as an alternative to chemotherapy and has been commonly viewed as a “game changer” for its potential to improve survival in a small proportion of patients. 1 – 4 Randomized controlled trials

Full access

Anuhya Kommalapati, Sri Harsha Tella, Adams Kusi Appiah, Lynette Smith and Apar Kishor Ganti

. The Intergroup 0139 study demonstrated an improvement in 5-year progression-free survival and local control with surgical resection after neoadjuvant chemoradiotherapy. 6 A trend toward improved overall survival (OS) was seen in the surgery group